Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hair loss protein target revealed? minoxidil study probes JAK2

NCT ID NCT07563036

Knowledge-focused Sponsor: Kasr El Aini Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will measure a protein called JAK2 in the scalps of 25 people with male pattern baldness. Researchers will compare JAK2 levels in balding and non-balding areas, then see if 12 weeks of topical minoxidil 5% changes JAK2 in the balding scalp. The goal is to understand whether JAK2 is involved in hair loss and how minoxidil might work at the tissue level.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Topical minoxidil 5% solution
What this could lead to
If successful, this could reveal whether JAK2 plays a role in hair loss and whether minoxidil works through this pathway, pointing toward new treatment targets.
What could go wrong
This is a very small, early study with only 25 participants and no control group. It measures a protein level, not hair regrowth directly, so results may not lead to a practical treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male adults aged 18 to 50 years with androgenetic alopecia. * Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V. * Patients who are treatment-naive or willing to undergo an adequate washout period for prior hair loss therapies of at least 1 month. * Willing and able to provide written informed consent. Exclusion Criteria: * Other types of hair loss, including inflammatory or scarring alopecia. * Inflammatory scalp dermatoses, such as psoriasis or seborrheic dermatitis. * Use of systemic immunosuppressants, JAK inhibitors, or systemic corticosteroids within the last 12 months. * History of severe systemic disease, including renal, cardiovascular, or hepatic disease. * Chemotherapy during the last 5 years. * Bleeding disorders.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenetic alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Androgenetic alopecia Androgenic alopecia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kasr El Aini Hospital

    RECRUITING

    Cairo, Cairo Governorate, 11555, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.